Verrica Pharmaceuticals Inc (VRCA) FinancialsVRCAFinancialVerrica Pharmaceuticals Inc

Evaluating the bottom line, Verrica Pharmaceuticals Inc maintains a gross margin of 85.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -194.46%, while the net margin is -224.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VRCA converts its operational activities into shareholder value.

In the context of the broader market, VRCA competes directly with industry leaders such as YARW and PTHS. With a market capitalization of $97.75M, it holds a leading position in the sector. When comparing efficiency, VRCA's gross margin of 85.02% stands against YARW's 100.00% and PTHS's 70.18%. Such benchmarking helps identify whether Verrica Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Verrica's gross margin has been strong, reaching 96.11% in Q2 2025, indicating potential for profitability as revenues increase. However, the company reported a net loss of $13.2 million in Q2 2026, which raises concerns about its financial health.